Anavex Announces Uplisting to NASDAQ

NEW YORK, NY – October 26, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the Company has received approval to begin trading its common stock on the…

Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference

NEW YORK, NY – October 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data…